Microba Life Sciences Limited Reports Strong Core Growth and Advance Commercail Expansion
Microba Life Sciences Limited (ASX: MAP) delivered a strong FY26 performance, driven by accelerating demand for its core microbiome testing business and continued progress in commercial execution. Core testing volume increased 78% year-on-year to 22,418 tests, while core testing revenue surged 92%, supported by a record Q4 in which test volumes rose 54% and annualised throughput exceeded 25,000 tests. The company strengthened its Australian enterprise strategy by signing 43 key healthcare accounts, with more than 175 additional targets in its pipeline. In the United Kingdom, Microbiome Explorer continued gaining traction, recording 92% growth in quarterly test sales.
Microba also remains on track to launch its GI Navigator diagnostic platform in September 2026 after a successful early-access rollout, while its Invivo branded supplements business continued delivering steady growth. The therapeutics division advanced partnering discussions for its microbiome drug pipeline, including MAP-315, supported by positive sector developments and ongoing clinical validation. Operational streamlining is expected to reduce annual cash costs by more than AU$7 million, reinforcing the company's pathway toward cashflow break-even. A strengthened cash position following a AU$5.0 million placement further supports execution of its FY27 growth strategy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Microba Life Sciences Limited Reports Strong Core Growth and Advance Commercail Expansion
Microba Life Sciences Limited (ASX: MAP) delivered a strong FY26 performance, driven by accelerating demand for its core microbiome testing business and continued progress in commercial execution. Core testing volume increased 78% year-on-year to 22,418 tests, while core testing revenue surged 92%, supported by a record Q4 in which test volumes rose 54% and annualised throughput exceeded 25,000 tests. The company strengthened its Australian enterprise strategy by signing 43 key healthcare accounts, with more than 175 additional targets in its pipeline. In the United Kingdom, Microbiome Explorer continued gaining traction, recording 92% growth in quarterly test sales.
Microba also remains on track to launch its GI Navigator diagnostic platform in September 2026 after a successful early-access rollout, while its Invivo branded supplements business continued delivering steady growth. The therapeutics division advanced partnering discussions for its microbiome drug pipeline, including MAP-315, supported by positive sector developments and ongoing clinical validation. Operational streamlining is expected to reduce annual cash costs by more than AU$7 million, reinforcing the company's pathway toward cashflow break-even. A strengthened cash position following a AU$5.0 million placement further supports execution of its FY27 growth strategy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au